Prudential Financial Inc. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 87,674 shares of the biopharmaceutical company’s stock after buying an additional 4,800 shares during the quarter. Prudential Financial Inc. owned 0.08% of Alnylam Pharmaceuticals worth $6,362,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Price Wealth Management Inc. acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $46,000. Capital Investment Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $25,000. Baillie Gifford & Co. increased its stake in Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock valued at $450,850,000 after buying an additional 528,966 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Alnylam Pharmaceuticals by 7.4% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,669 shares of the biopharmaceutical company’s stock valued at $1,064,000 after buying an additional 1,011 shares during the period. Finally, Monashee Investment Management LLC increased its stake in Alnylam Pharmaceuticals by 1,614.3% in the 2nd quarter. Monashee Investment Management LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $4,354,000 after buying an additional 56,500 shares during the period. Hedge funds and other institutional investors own 94.26% of the company’s stock.
Several research firms have commented on ALNY. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 4th. Barclays reissued a “buy” rating and issued a $125.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. Piper Jaffray Companies set a $145.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. ValuEngine raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and an average target price of $116.13.
Shares of ALNY stock traded down $2.31 during mid-day trading on Thursday, reaching $83.86. The company’s stock had a trading volume of 14,987 shares, compared to its average volume of 843,388. Alnylam Pharmaceuticals, Inc. has a 1-year low of $60.27 and a 1-year high of $99.73. The company has a market cap of $9.45 billion, a P/E ratio of -11.09 and a beta of 2.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. The firm’s 50-day moving average is $79.70 and its two-hundred day moving average is $78.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The company had revenue of $38.20 million during the quarter, compared to analysts’ expectations of $42.24 million. During the same quarter in the prior year, the company posted ($1.61) EPS. The business’s revenue was up 27.8% on a year-over-year basis. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.